FDA Approves Insulet's Omnipod 5 for Type 2 Diabetes in Adults

Aug 27, 2024, 12:40 PM

The U.S. Food and Drug Administration (FDA) has granted clearance for the Omnipod® 5 Automated Insulin Delivery System, developed by Insulet Corp, to be used by individuals with Type 2 diabetes. This marks the first time an automated insulin dosing device has been approved for Type 2 diabetes patients, specifically those aged 18 and older. The device, which incorporates Insulet's SmartAdjust technology, aims to simplify diabetes management by automating insulin delivery, potentially reducing errors and improving patient outcomes. With approximately 30 million Americans diagnosed with Type 2 diabetes, of which 6 million require insulin and 2.5 million are on multiple daily injections, this development could significantly impact diabetes care. The FDA's decision is part of a broader effort to increase access to innovative diabetes management technologies. Insulet's stock, trading under the ticker $PODD, saw a 1.5% increase in pre-market trading following the announcement.